Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.
Florian HitzenbichlerArno MohrDaniele CamboniMichaela SimonBernd SalzbergerFrank HansesPublished in: Infection (2020)
We present four cases with Gram-positive bacteremia (pathogens: MRSA n = 1, Enterococcus spp. n = 3) due to an intravascular source (left ventricular assist device: n = 2, transfemoral aortic valve implantation n = 1, prosthetic aortic valve: n = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.
Keyphrases
- aortic valve
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- gram negative
- end stage renal disease
- aortic valve replacement
- aortic stenosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- heart failure
- staphylococcus aureus
- escherichia coli
- metabolic syndrome
- left ventricular
- cystic fibrosis
- methicillin resistant staphylococcus aureus
- cell therapy
- rectal cancer
- smoking cessation